Genitourinary Tumors (Bladder Cancer, Kidney Cancer, Prostate Cancer)
Conditions
Interventions
Urinary Tumor Group:None
Non-cancer Control Group:None
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Urological Tumor Subjects 1. Age over 18 years and under 80 years, no gender restriction. 2. Histologically and/or cytologically diagnosed with urothelial carcinoma, renal cell carcinoma, or prostate cancer. 3. Comprehensive clinical and pathological information is obtainable. 4. Subjects have read and fully understood the patient information sheet and signed the informed consent form. Translated with DeepL.com (free version); Non-Cancer Control Population Inclusion Criteria 1. Age over 45 years old and under 80 years old, no gender restriction; 2. No evidence of any tumors or suspicious nodules identified through systematic examination; 3. Subjects determined to be healthy through systematic examination, with no other major chronic diseases including cardiovascular and cerebrovascular diseases, chronic respiratory diseases, diabetes, stage III hypertension, acute or subacute severe hepatitis, etc.; 4. The subject has read and fully understood the patient information sheet and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Female subjects who are pregnant or currently breastfeeding; 2. Subjects with a current diagnosis of tumors other than urinary tract tumors, or with a history of prior tumors; 3. Subjects who have received any form of tumor treatment prior to enrollment, including surgery, radiotherapy/chemotherapy, targeted therapy, or immunotherapy; 4. Organ transplant recipients or individuals who have previously undergone non-autologous (allogeneic) bone marrow or stem cell transplantation; 5. Individuals with febrile illnesses, or those requiring medical treatment for acute episodes or inflammatory diseases within 14 days prior to enrollment; 6. Any other clinically significant disease or condition deemed by the investigator to potentially affect protocol compliance, compromise the patient's ability to provide informed consent, or render the patient unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the ROC Curve (AUC);Specificity;Sensitivity; | — |
Countries
China
Contacts
Public ContactJiahua Pan
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed